Insider Trading Alert - VAR, RIG, CHMT, WDAY And CACI Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Dec. 5, 2013, 115 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $322.40 to $43,442,751.80.

Highlighted Stocks Traded by Insiders:

Varian Medical Systems (VAR) - FREE Research Report

Kluge Robert H who is Corp SVP; Pres. X-Ray Products at Varian Medical Systems sold 12,932 shares at $80.00 on Dec. 5, 2013. Following this transaction, the Corp SVP; Pres. X-Ray Products owned 20,347 shares meaning that the stake was reduced by 38.86% with the 12,932-share transaction.

The shares most recently traded at $79.08, down $0.92, or 1.16% since the insider transaction. Historical insider transactions for Varian Medical Systems go as follows:

  • 4-Week # shares sold: 2,972
  • 12-Week # shares sold: 4,219
  • 24-Week # shares sold: 10,021

The average volume for Varian Medical Systems has been 818,300 shares per day over the past 30 days. Varian Medical Systems has a market cap of $8.4 billion and is part of the health care sector and health services industry. Shares are up 12.26% year-to-date as of the close of trading on Thursday.

Varian Medical Systems, Inc. designs, manufactures, sells, and services medical devices and software for treating cancer with radiotherapy, radiosurgery, proton therapy, and brachytherapy worldwide. The company has a P/E ratio of 20.1. Currently there are 6 analysts that rate Varian Medical Systems a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VAR - FREE

TheStreet Quant Ratings rates Varian Medical Systems as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in stock price during the past year, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Varian Medical Systems Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Transocean (RIG) - FREE Research Report

Toma Ihab Magdy who is EVP & Chief of Staff at Transocean sold 20,000 shares at $50.07 on Dec. 5, 2013. Following this transaction, the EVP & Chief of Staff owned 3,315 shares meaning that the stake was reduced by 85.78% with the 20,000-share transaction.

The shares most recently traded at $49.72, down $0.35, or 0.7% since the insider transaction.

The average volume for Transocean has been 5.8 million shares per day over the past 30 days. Transocean has a market cap of $18.1 billion and is part of the basic materials sector and energy industry. Shares are up 11.31% year-to-date as of the close of trading on Thursday.

Transocean Ltd. provides offshore contract drilling services for oil and gas wells worldwide. It offers deepwater and harsh environment drilling, oil and gas drilling management, and drilling engineering and drilling project management services, as well as logistics services. The stock currently has a dividend yield of 4.45%. The company has a P/E ratio of 11.3. Currently there are 6 analysts that rate Transocean a buy, 3 analysts rate it a sell, and 12 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on RIG - FREE

TheStreet Quant Ratings rates Transocean as a buy. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, revenue growth, attractive valuation levels, increase in stock price during the past year and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Transocean Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Chemtura Corporation (CHMT) - FREE Research Report

Cross Chet who is EVP, Supply Chain & Operations at Chemtura Corporation sold 1,200 shares at $25.97 on Dec. 5, 2013. Following this transaction, the EVP, Supply Chain & Operations owned 77,172 shares meaning that the stake was reduced by 1.53% with the 1,200-share transaction.

The shares most recently traded at $26.25, up $0.28, or 1.07% since the insider transaction. Historical insider transactions for Chemtura Corporation go as follows:

  • 4-Week # shares sold: 1,000
  • 12-Week # shares sold: 1,000
  • 24-Week # shares sold: 1,000

The average volume for Chemtura Corporation has been 781,300 shares per day over the past 30 days. Chemtura Corporation has a market cap of $2.5 billion and is part of the basic materials sector and chemicals industry. Shares are up 21.12% year-to-date as of the close of trading on Thursday.

Chemtura Corporation, together with its subsidiaries, engages in the manufacture and sale of specialty chemical solutions and consumer products worldwide. The company has a P/E ratio of 184.9. Currently there are 5 analysts that rate Chemtura Corporation a buy, 1 analyst rates it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CHMT - FREE

TheStreet Quant Ratings rates Chemtura Corporation as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. Get the full Chemtura Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Workday (WDAY) - FREE Research Report

Bhusri Aneel who is Co-CEO and Chairman at Workday sold 62,500 shares at $78.96 on Dec. 5, 2013. Following this transaction, the Co-CEO and Chairman owned 508,510 shares meaning that the stake was reduced by 10.95% with the 62,500-share transaction.

The shares most recently traded at $80.96, up $2.00, or 2.48% since the insider transaction. Historical insider transactions for Workday go as follows:

  • 12-Week # shares sold: 37,500
  • 24-Week # shares sold: 128,165

The average volume for Workday has been 1.0 million shares per day over the past 30 days. Workday has a market cap of $6.2 billion and is part of the technology sector and computer software & services industry. Shares are up 50.13% year-to-date as of the close of trading on Thursday.

Workday, Inc. provides enterprise cloud-based applications for enterprises in the United States and internationally. It offers applications for customers to manage critical business functions that enable them to optimize their financial and human capital resources. Currently there are 8 analysts that rate Workday a buy, no analysts rate it a sell, and 13 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on WDAY - FREE

TheStreet Quant Ratings rates Workday as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income and feeble growth in its earnings per share. Get the full Workday Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

CACI International (CACI) - FREE Research Report

Blue Harbour Group, LP who is 10% Owner at CACI International bought 17,144 shares at $71.91 on Dec. 5, 2013. Following this transaction, the 10% Owner owned 2.4 million shares meaning that the stake was reduced by 0.73% with the 17,144-share transaction.

The shares most recently traded at $73.50, up $1.59, or 2.17% since the insider transaction. Historical insider transactions for CACI International go as follows:

  • 4-Week # shares sold: 13,447
  • 12-Week # shares sold: 22,978
  • 24-Week # shares sold: 23,953

The average volume for CACI International has been 196,400 shares per day over the past 30 days. CACI International has a market cap of $1.7 billion and is part of the services sector and diversified services industry. Shares are up 32.02% year-to-date as of the close of trading on Thursday.

CACI International Inc., together with its subsidiaries, provides information solutions and services to the U.S. federal government and commercial markets in North America and internationally. The company has a P/E ratio of 11.8. Currently there are 2 analysts that rate CACI International a buy, 3 analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CACI - FREE

TheStreet Quant Ratings rates CACI International as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures and attractive valuation levels. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full CACI International Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research
null

If you liked this article you might like

Centene, LabCorp Among Healthcare Stock Gainers

Centene, LabCorp Among Healthcare Stock Gainers

There Is Good and a Lot of Bad in General Electric Earnings

There Is Good and a Lot of Bad in General Electric Earnings

7 Investment Themes You Can't Afford to Miss for 2018

7 Investment Themes You Can't Afford to Miss for 2018

PerkinElmer Takes Cautious Approach to M&A

PerkinElmer Takes Cautious Approach to M&A

Here's How Health-Care Reform Will Affect This Cancer Care Company

Here's How Health-Care Reform Will Affect This Cancer Care Company